Icure Pharmaceutical's Shareholders' Meeting Petition Withdrawn by IK Partners Group, Reducing Management Dispute Risk


  • Icure Pharmaceutical disclosed that the petition for permission to convene a shareholders' meeting filed by IK Partners and 75 others has been withdrawn.
  • This is related to the management dispute lawsuit filed on March 9, 2026, and the withdrawal suggests a potential resolution of the legal conflict.
  • The removal of immediate threat to current management is expected to contribute to shareholder value stabilization.
  • [AI Summary]Withdrawal of management dispute without capital changes reduces governance risk, positive for short-term stock price stability.

KOSDAQ Filing Information


  • Judgment/Decision on Lawsuit, etc. (Permission to Convene a General Meeting of Shareholders)
  • Company: Icure Pharmaceutical (175250)
  • Submission: Icure Pharmaceutical Incorporation
  • Under KRX KOSDAQ Market Division

  • Shares: 37,558,368
  • Price: 2,170 KRW
  • Market Cap: 81.5 B KRW